MetP Pharma
MetP Pharma AG specializes in nasal drug delivery technology, offering a fully developed and proven platform called MetP that enables effective delivery of drugs to the brain and systemic circulation via nasal application. Their platform includes a semi-solid gel matrix Silcum, a single-dose nasal applicator Lecticula, and a filling technology Maxima. The company focuses on in-house product development, licensing to partners, and providing innovative solutions for neurological and other medical conditions, with a strong emphasis on safety, efficacy, and patent protection.
Industries
Nr. of Employees
small (1-50)
MetP Pharma
Schynweg 7, Office: St. Anna-Weg 16, P.O.Box 138, 6376 Emmetten / Switzerland
Products
Preservative-free OTC nasal gel formulation for allergic rhinitis (marketed)
Preservative-free nasal OTC formulation developed for the reduction of allergic nasal symptoms and secretion and support of nasal mucosa regeneration; stated as commercialized in several countries.
Nasal testosterone replacement formulation (Phase III referenced)
Nasal formulation intended for testosterone replacement therapy in adult males; described as in Phase III in company materials.
Nasal dopamine formulation for CNS delivery (preclinical)
Preclinical-stage nasal formulation developed to deliver dopamine directly to the brain for indications such as attention deficit hyperactivity disorder, intended to bypass the blood-brain barrier.
Nasal formulations for neuroprotective and cognitive indications (pregnenolone, progesterone; preclinical)
Preclinical nasal formulations intended for indications such as mild cognitive impairment, insomnia and concussion (mild traumatic brain injury), developed to provide neuroprotective effects and cognitive enhancement via nasal delivery.
Preservative-free OTC nasal gel formulation for allergic rhinitis (marketed)
Preservative-free nasal OTC formulation developed for the reduction of allergic nasal symptoms and secretion and support of nasal mucosa regeneration; stated as commercialized in several countries.
Nasal testosterone replacement formulation (Phase III referenced)
Nasal formulation intended for testosterone replacement therapy in adult males; described as in Phase III in company materials.
Nasal dopamine formulation for CNS delivery (preclinical)
Preclinical-stage nasal formulation developed to deliver dopamine directly to the brain for indications such as attention deficit hyperactivity disorder, intended to bypass the blood-brain barrier.
Nasal formulations for neuroprotective and cognitive indications (pregnenolone, progesterone; preclinical)
Preclinical nasal formulations intended for indications such as mild cognitive impairment, insomnia and concussion (mild traumatic brain injury), developed to provide neuroprotective effects and cognitive enhancement via nasal delivery.
Services
End-to-end pharmaceutical development of nasal formulations intended for licensing to partners, including formulation adaptation, preclinical and proof-of-concept studies and regulatory-supporting documentation in consultation with the partner.
On-site manufacturing and fill-finish capacity for mono-dose nasal applicators meeting ISO and GMP standards, providing pilot sample production and commercial-scale throughput.
Support and execution of preclinical studies and clinical proof-of-concept studies for nasal formulations, including study design consultation and sample supply for trials.
End-to-end pharmaceutical development of nasal formulations intended for licensing to partners, including formulation adaptation, preclinical and proof-of-concept studies and regulatory-supporting documentation in consultation with the partner.
On-site manufacturing and fill-finish capacity for mono-dose nasal applicators meeting ISO and GMP standards, providing pilot sample production and commercial-scale throughput.
Support and execution of preclinical studies and clinical proof-of-concept studies for nasal formulations, including study design consultation and sample supply for trials.
Expertise Areas
- Intranasal and nose-to-brain drug delivery
- Formulation development for semi-solid bioadhesive matrices
- Single-dose nasal applicator design and manufacture
- Fill-finish and scale-up for mono-dose nasal products
Key Technologies
- Semi-solid bioadhesive gel formulations
- Single-use mono-dose nasal applicators
- High-throughput filling and packaging lines for mono-dose devices
- Nose-to-brain delivery via olfactory and trigeminal pathways